StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > BABY STEPS

<< Previous

Bullboard Posts

Next >>

Comment by capebretongirlon Jul 14, 2021 10:22am

125 Views

Post# 33541974

RE:RE:BABY STEPS

No doubt Aristotle/AVRT revenue will be the story of the future. However, no one can argue that solid covid revenue versus no revenue for Q2 is a much better thing. If anyone thinks we would be better off these days with zero covid dollars, then they are mistaken.

frewil11 wrote: The market will not like Q2 results one bit , it is good that the company will have brought in good revenue from Covid testing but it will be zero from aristotle wich the market will not like .

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market